Uitspraak
AMSTERDAM DISTRICT COURT
1.the private company with limited liability
1.Procedural history
inter aliaconfirmed that EUR 84,012.43 had been paid to [claimant] .
2.The facts
inter aliato incorporate two companies in the Philippines: a production company and a distribution company. In addition, [claimant] agreed to effect the official registration of the Debx-products with the Food and Drug Administration (FDA) of the Philippines.
( [A] ), with copy to [X] and to the CEO and director of Debx, [B]
( [B] ), [claimant] wrote as follows:
, [X][the Court: [X] ]
en ik en als vijfde vraag ik mijn Filippijnse advokaat. Is dat ok wat jullie betreft (…)."
and all attorneys of his office first be the incorporators and directors as we all(you, [B][the Court: [B] ]
, [X][the Court: [X] ]
and me) don't want to be liable at first with selling and marketing a product that might not be officially FDA registered yet. (…)."
zal
,
) worked out and have the texting sharp, for this reason, I am asking [C] (…) to comment and provide some further details and perhaps optimization on the communication front. (…)."
inter aliathe Debx products that had been made available to [claimant] , including 28 test samples (ampoules) of the wound care product called “ [the product] ”. Debx based this claim on the confidentiality clause in the MOU and on the Non Disclosure Agreement that Debx Medical and [claimant] had entered into prior to the MOU. Debx also requested confirmation (supported by a written statement from an IT expert or an accountant) that [claimant] did not retain any copies of the data and that [claimant] would maintain confidentiality in all other respects. Debx also disputed the payment of the incurred costs.
3.The claim
4.Discussion
- i) in his email dated 29 April 2020, [claimant] claimed EUR 92,000.00;
- ii) in his writ of summons dated 13 July 2020, [claimant] claimed EUR 88,604.60 or the euro equivalent of USD 100,000.00;
- iii) in his amended claim, [claimant] claims EUR 6,937.57 (see above, sub 3.1.).
Debx already did recognise this obligation on 1 May 2020, shortly after it had terminated the MOU, in response to [claimant] ’s demand email of 29 April 2020 in which repayment of the advance payment in euros was claimed. [claimant] claimed payment before 6 May 2020 at the latest. He did not agree to payment in (four) instalments, as was subsequently proposed by Debx. Debx had no right to suspend repayment on the basis of its claim that [claimant] had a reciprocal obligation to
inter aliareturn all confidential information pursuant to the MOU and the Non Disclosure Agreement (see above, sub 2.13.). This obligation was not yet due when [claimant] demanded payment (and Debx recognised its obligation to do so). The Non Disclosure Agreement stipulates that such obligation only arises after Debx’s written request to that effect. This request was first made on 14 May 2020, in an email of Debx’s lawyer, at which time Debx was already in default with respect to its obligation to repay the advance payment. Although Debx stated at the court hearing that the Non Disclosure Agreement should be disregarded in this respect, it did not explain why. The mere fact that the confidentiality clause in the MOU states that confidential data should be returned if the contemplated cooperation between the parties is not completed, does not in itself justify Debx’s suspension of the repayment either.
for the creation of a website. [claimant] argues that these costs have been incurred solely for the purpose of the contemplated cooperation, in accordance with clause 9.4 of the MOU (see above sub 2.10.), and should be borne by Debx. As Debx unilaterally terminated the contemplated cooperation with [claimant] , it should bear the consequences of the termination and reimburse [claimant] for the costs he incurred.
inter aliatwo companies had to be incorporated in the Philippines, one for the production and one for the distribution of Debx products. In this regard, articles of incorporation and by-laws for the distribution company were drafted (by Suarez’s firm) and sent to Debx, as one of its envisaged shareholders. The lawyer’s fees incurred by [claimant] for these legal services are recognised as such by Debx and Debx did not bring forward any facts or circumstances that could lead to the conclusion that [claimant] or Suarez was asked by Debx to terminate these legal services.
USD 15,000.00 to be a reasonable fee for the lawyer’s services. It will order Debx to pay this amount to [claimant] to reimburse him for lawyer’s fees incurred.
'amazing work') and made comments to its substance as well. This means that not only did Debx approve that [claimant] and [X] had a website built, but also that Debx participated in the creation of this new website. Debx’s argument that a Debx website was already operational, is not supported by facts and cannot be upheld. The circumstance that the content of the website had to be corrected by [B] from a medical point of view, does not alter the fact that (website) building costs were incurred by [claimant] . Except for the costs for 'Web Hosting and Maintenance (yearly)' and 'Design and Printing Debx Calling Cards', as referred to in the invoice of the website builder (see above, sub 2.9.), the Court considers the remaining
The statutory interest claimed by [claimant] pursuant to Article 6:119a DCC cannot be allowed. The incurred costs do not arise from a commercial contract in the context of Article 6:119a DCC between [claimant] and Debx. Therefore, the Court will award the statutory interest due under Article 6:119 DCC on the sum of the incurred costs of USD 24,695.00. The statutory interest cannot be allowed as of 27 April 2020, the date of the termination of the MOU. [claimant] has insufficiently substantiated that the incurred costs were due at that time. Therefore, the statutory interest will be allowed from the date of the writ of summons, 13 July 2020.
EUR 6,000.00(3 x EUR 2,000.00)
nakosten) will be allowed plus statutory interest (Article 6:119 DCC) on (all) the costs of these proceedings, as stated in the decision.